Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience

Journal Article (Journal Article)

Replication-competent retrovirus (RCR) is a safety concern for individuals treated with retroviral gene therapy. RCR detection assays are used to detect RCR in manufactured vector, transduced cell products infused into research subjects, and in the research subjects after treatment. In this study, we reviewed 286 control (n = 4) and transduced cell products (n = 282) screened for RCR in the National Gene Vector Biorepository. The transduced cell samples were submitted from 14 clinical trials. All vector products were previously shown to be negative for RCR prior to use in cell transduction. After transduction, all 282 transduced cell products were negative for RCR. In addition, 241 of the clinical trial participants were also screened for RCR by analyzing peripheral blood at least 1 month after infusion, all of which were also negative for evidence of RCR infection. The majority of vector products used in the clinical trials were generated in the PG13 packaging cell line. The findings suggest that screening of the retroviral vector product generated in PG13 cell line may be sufficient and that further screening of transduced cells does not provide added value.

Full Text

Duke Authors

Cited Authors

  • Cornetta, K; Duffy, L; Feldman, SA; Mackall, CL; Davila, ML; Curran, KJ; Junghans, RP; Tang, JY; Kochenderfer, JN; O'Cearbhaill, R; Archer, G; Kiem, HP; Shah, NN; Delbrook, C; Kaplan, R; Brentjens, RJ; Rivière, I; Sadelain, M; Rosenberg, SA

Published Date

  • September 21, 2018

Published In

Volume / Issue

  • 10 /

Start / End Page

  • 371 - 378

Electronic International Standard Serial Number (EISSN)

  • 2329-0501

Digital Object Identifier (DOI)

  • 10.1016/j.omtm.2018.08.006

Citation Source

  • Scopus